Literature DB >> 31152570

Dual delivery of encapsulated BM-MSCs and BMP-2 improves osteogenic differentiation and new bone formation.

Ying Kong1, Yuan Zhao2, Dong Li3, Hongwei Shen4, Mingming Yan5.   

Abstract

Stem cell-based therapies provide a promising approach for bone repair. In the present work, we developed a novel 3D vehicle system for dual-delivery of encapsulated bone marrow mesenchymal stem cells (BM-MSCs) and bone morphogenetic protein-2 (BMP-2) for treatment of large bone defects. The vehicle system consists of sodium alginate microcapsules and polylactic acid (PLLA) microspheres. BM-MSCs are encapsulated in the microcapsules, and BMP-2 proteins are encapsulated in the PLLA microspheres. This vehicle system acted as a multicore structure for sustained release of BMP-2, which enabled pulsed dosing induction of osteogenic differentiation of the co-embedded BM-MSCs. in vitro experiments showed that the loaded BMP-2 was constitutively released up to 30 days. Bioactivity of the incorporated BMP-2 in the microspheres was preserved and osteogenic differentiation of the BM-MSCs in the microcapsules was improved. In vivo, osteogenesis studies demonstrated that satisfactory degree of repair of a rat calvarial defect was achieved with the delivery of either encapsulated BM-MSCs alone or encapsulated BMP-2 alone. Transplantation of encapsulated both BM-MSCs and BMP-2 exhibited the greatest repair potential following 4- or 8-weeks treatment. In conclusion, microencapsulation of BM-MSCs and BMP-2 promoted the maturity of newly generated bone and improved new bone formation. Transplantation of BM-MSCs and BMP-2 in our novel 3-D vehicle system is a promising strategy for regenerative therapies of large bone defects.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  BM-MSCs; BMP-2; bone regeneration; dural delivery; multicore PLA microspheres

Year:  2019        PMID: 31152570     DOI: 10.1002/jbm.a.36737

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  6 in total

1.  Msx2 plays an important role in BMP6-induced osteogenic differentiation of two mesenchymal cell lines: C3H10T1/2 and C2C12.

Authors:  Chuan Cai; Jing Wang; Na Huo; Li Wen; Peng Xue; Ye Huang
Journal:  Regen Ther       Date:  2020-05-15       Impact factor: 3.419

2.  Cotransplantation of mesenchymal stem cells and endothelial progenitor cells for treating steroid-induced osteonecrosis of the femoral head.

Authors:  Haixia Xu; Chengqiang Wang; Chun Liu; Ziyue Peng; Jianjun Li; Yanglei Jin; Yihan Wang; Jiasong Guo; Lixin Zhu
Journal:  Stem Cells Transl Med       Date:  2021-01-13       Impact factor: 6.940

Review 3.  Poly(Lactic Acid)-Based Microparticles for Drug Delivery Applications: An Overview of Recent Advances.

Authors:  Antonios Vlachopoulos; Georgia Karlioti; Evangelia Balla; Vasileios Daniilidis; Theocharis Kalamas; Myrika Stefanidou; Nikolaos D Bikiaris; Evi Christodoulou; Ioanna Koumentakou; Evangelos Karavas; Dimitrios N Bikiaris
Journal:  Pharmaceutics       Date:  2022-02-04       Impact factor: 6.321

Review 4.  Steroid-Induced Osteonecrosis of the Femoral Head: Novel Insight Into the Roles of Bone Endothelial Cells in Pathogenesis and Treatment.

Authors:  Cheng Huang; Zeqin Wen; Junjie Niu; Subin Lin; Weiguo Wang
Journal:  Front Cell Dev Biol       Date:  2021-11-30

Review 5.  The therapeutic potential of mesenchymal stem cells in treating osteoporosis.

Authors:  Tianning Chen; Tieyi Yang; Weiwei Zhang; Jin Shao
Journal:  Biol Res       Date:  2021-12-20       Impact factor: 5.612

6.  FOXO3 is targeted by miR-223-3p and promotes osteogenic differentiation of bone marrow mesenchymal stem cells by enhancing autophagy.

Authors:  Cheng Long; Shiqiang Cen; Zhou Zhong; Chang Zhou; Gang Zhong
Journal:  Hum Cell       Date:  2020-09-13       Impact factor: 4.174

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.